HedgePath launches clinical trial for proposed cancer treatment
HPPI will study the efficacy and safety of twice-daily dosing of SUBA-Itraconazole Oral Capsules as a potential therapy for basal cell carcinoma (BCC) in patients with basal cell
Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and machine learning (ML).
Both studies met all primary immunogenicity endpoints, demonstrating robust immune responses against certain invasive meningococcal B strains after the vaccine dose series. Safety and tolerability data from both
Ofatumumab, a fully human monoclonal antibody currently being designed for relapsing remitting multiple sclerosis (RRMS) and other autoimmune indications, targets CD20 and is administered by subcutaneous injection. Previously,